Non-Competitive N-Methyl D-Aspartate (NMDA) Receptor Antagonists

DBCAT005693Pharmacologic class

Antagonists of NMDA receptors which exert their antagonism via binding to allosteric sites. A DrugBank category of 1 drug. 1 of them is approved.

Part of: NMDA Receptor Antagonists
Drugs: Esketamine

What you can answer from here — as of November 29, 2022

1DrugEach linked to its full drug card

Listed above

5Drug targetsEvery drug–target pair in the class, with bond type

29Marketed productsAcross the regions we cover, with dosage forms and routes

4Routes of administrationHow the drugs in this class are given

Which targets do Non-Competitive N-Methyl D-Aspartate (NMDA) Receptor Antagonists share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account